Illumina’s multibillion-dollar quest for Grail—high-reaching, yet ultimately doomed—is nearing its conclusion. The DNA ...

A clinical study found that an at-home test based on the DNA found in spit samples could detect cases of prostate cancer that ...

Women have long shouldered the burden of birth control. Now, men may soon have an option that is not only hormone-free, but ...

BD is stretching its reach in patient monitoring with the $4.2 billion purchase of Edwards Lifesciences’ connected care ...

As Keytruda’s 2028 patent cliff looms large, Merck & Co.’s renewed R&D oncology strategy focuses on three strategies. | As ...

Rapport Therapeutics is talking up a $122 million IPO, the first in a return to public market interest since an earlier rush ...

Now that’s more like it. After investors frowned on Structure Therapeutics’ oral GLP-1 data in December 2023, the biotech is ...

Arrowhead Pharmaceuticals’ RNA interference (RNAi) therapeutic lowered triglycerides in patients with a rare metabolic ...

Pharmas have a record $1 trillion to deploy on new biotech innovation deals. All they need is for the Federal Reserve to ...

Eli Lilly is splicing another asset onto its neurodegenerative disease pipeline, paying QurAlis $45 million for rights to a preclinical treatment for amyotrophic lateral sclerosis (ALS) and ...

ConcertAI also announced three new AI products at ASCO. The first, Cara AI, is an AI-based platform with tools that curate ...